GSK and Google parent to fight diseases
Print Edition
GLAXOSMITHKLINE and Google parent Alphabet’s life sciences unit are creating a new company focused on fighting diseases by targeting electrical signals in the body, jump-starting a novel field of medicine called bioelectronics.
Verily Life Sciences — known as Google’s life sciences unit until last year — and Britain’s biggest drugmaker will together contribute 540 million pounds (US$715 million) over seven years to Galvani Bioelectronics, they said yesterday.
The new company, owned 55 percent by GSK and 45 percent by Verily, will be based at GSK’s Stevenage research center north of London, with a second research hub in South San Francisco.
It is GSK’s second notable investment in Britain since the country voted to leave the European Union in June. Last week it unveiled plans to spend 275 million pounds on drug manufacturing.
Galvani will develop miniaturized, implantable devices that can modify electrical nerve signals. The aim is to modulate irregular or altered impulses that occur in many illnesses.
GSK believes chronic conditions such as diabetes, arthritis and asthma could be treated using these tiny devices, which consist of a electronic collar that wraps around nerves.
Kris Famm, GSK’s head of bioelectronics research and president of Galvani, said the first bioelectronic medicines using these implants to stimulate nerves could be submitted for regulatory approval by around 2023.
“We have had really promising results in animal tests, where we’ve shown we can address some chronic diseases with this mechanism, and now we are bringing that work into the clinic,” he said.
“Our goal is to have our first medicines ready for regulatory approval in seven years.”
GSK first unveiled its aims in bioelectronics in a paper in the journal Nature three years ago and believes it is ahead of Big Pharma rivals in developing medicines that use electrical impulses rather than traditional chemicals or proteins.
The tie-up shows the growing convergence of healthcare and technology. Verily already has several other medical projects in the works.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
